Biomind Labs, Inc. is a biotech research and development company focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is headquartered in Toronto, Ontario and currently employs 5 full-time employees. The company went IPO on 2021-07-27. The company is focused on transforming biomedical sciences knowledge into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, Biomind Labs is developing novel pharmaceutical formulations of key endogenous substances which are occurring in the human body and an organic compound that includes many neurotransmitters for treating a range of therapeutic indications. DMT is a serotonergic psychedelic that exerts its effects through serotonergic receptors in the brain, including 5-HT2A, 5-HT1A, 5-HT2C and 5-HT7 receptors. 5-MeO-DMT is a powerful psychedelic tryptamine. Under the 5-MeO-DMT Program, it is focused on two drug candidates: BMND05: 5-MeO-DMT novel formulation indicated for Chronic Pain and BMND08: 5-MeO-DMT novel formulation indicated for Alzheimer’s disease. Mescaline is a psychedelic alkaloid of the phenethylamine class.